887913-44-2

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 953741-63-4 rac-2-amino-2-(3-bromo-phenyl)-propionitrile 
• 1183013-69-5 (RS)-2-amino-2-(3-bromo-phenyl)-propan-1-ol 
• 887913-69-1 rac-[1-(3-bromo-phenyl)-2-hydroxy-1-methyl-ethyl]-carbamic acid tert-butyl ester 
• 1183581-39-6 (RS)-2-amino-2-(3-bromo-phenyl)-propionic acid methyl ester 

Downstream Products

• 887913-45-3 rac-[1-(3-bromo-phenyl)-1-methyl-2-methylamino-ethyl]-carbamic acid tert-butyl ester 
• 1353759-74-6 rac-N-[2-(3-bromo-phenyl)-2-tert-butoxycarbonylamino-propyl]-N-methyl-oxalamic acid ethyl ester 
• 1353759-75-7 rac-5-(3-bromo-phenyl)-1,5-dimethyl-piperazine-2,3-dione 
• 1353759-76-8 rac-5-(3-bromo-phenyl)-3-methoxy-1,5-dimethyl-5,6-dihydro-1H-pyrazin-2-one 
• 1353759-77-9 rac-3-amino-5-(3-bromo-phenyl)-1,5-dimethyl-5,6-dihydro-1H-pyrazin-2-one 
• 1353759-86-0 rac-3'-(6-amino-2,4-dimethyl-5-oxo-2,3,4,5-tetrahydro-pyrazin-2-yl)-biphenyl-3-carbonitrile 
• 1353759-87-1 rac-3-amino-5-[3-(5-methoxy-pyridin-3-yl)-phenyl]-1,5-dimethyl-5,6-dihydro-1H-pyrazin-2-one 
• 1369542-55-1 rac-N-[3-(6-amino-4-methyl-4,7-dihydropyrazolo[1,5-a]pyrazin-4-yl)-phenyl]-5-chloropyridine-2-carboxamide 
• 1369543-09-8 rac-4-(3-aminophenyl)-4-methyl-4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-amine 
• 1369543-06-5 rac-4-[3-((benzhydrylidene)amino)-phenyl]-4-methyl-4,7-dihydropyrazolo[1,5-a]pyrazin-6-amine 
• 1369543-05-4 rac-4-(3-bromophenyl)-4-methyl-4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-amine 
• 1369543-04-3 rac-4-(3-bromophenyl)-4-methyl-1-4,5-dihydro-pyrazolo[1,5-a]pyrazine-6-thione 
• 1369543-02-1 rac-4-(3-bromophenyl)-4-methyl-4,5-dihydro-pyrazolo[1,5-a]pyrazin-6-one 
• 1369542-99-3 rac-N-[1-(3-bromophenyl)-1-(1H-pyrazol-3-yl)ethyl]-2-chloro-acetamide 

Relevant academic research and scientific papers

3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA

The present invention relates to novel 3-amino-5,6-dihydro-1H-pyrazin-2-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical com

4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)

The present invention relates to novel 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-yl-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER?S DISEASE AND OTHER FORMS OF DEMENTIA

The present invention relates to novel 3-amino-5,6-dihydro-1H-pyrazin-2-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical com

4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)

The present invention relates to novel 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-yl- aminederivativesas inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretaseis involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associatedwith stroke, dementia associated with Parkinson's disease or dementia associated with beta- amyloid.